FDA reviewers concur with Aerie on Rhopressa's efficacy

Aerie Pharmaceuticals Inc. (NASDAQ:AERI) gained $8.95 (16%) to $64.30 on Wednesday after FDA released briefing documents ahead of an advisory committee meeting